A Multicenter Survival Analysis of Adults Type B‐Acute Lymphoblastic Leukemia in Ecuador. A Retrospective Study of the Real World
Cancer Medicine · 2026
DOI: 10.1002/cam4.71625 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, 2026. Verfasst von Brenner Sabando und 12 weiteren Autor:innen. Beteiligte Einrichtung: IRHED Medical Specialties Center, Guayaquil, Ecuador. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Varifarma Ecuador.
Abstract (Originalsprache)
Objective
To describe clinical characteristics, treatment outcomes, and overall survival (OS) of Ecuadorian adults with B‐cell acute lymphoblastic leukemia (B‐ALL).
Methods
A retrospective multicenter cohort study was conducted in patients > 15 years diagnosed with B‐ALL between 2015 and 2022 across eight tertiary centers in Ecuador. Medical records of 734 acute lymphoblastic leukemia cases classified by the 2016 WHO criteria were reviewed; 653 B‐ALL patients were included. Multiple frontline chemotherapy regimens were used, and Philadelphia‐positive (Ph+) cases were included.
Results
Among 653 patients, 50.4% were male, with a median age of 31 years (interquartile range, 20–47). Most (93%) received chemotherapy, achieving a complete remission (CR) rate of 53.3% (311/583) and minimal residual disease (MRD) negativity in 49.1% (211/430). Relapse occurred in 62.4% (194/310), and 16 of 164 underwent allogeneic hematopoietic stem cell transplantation (HSCT). Treatment‐related mortality was 31.5%, higher in pediatric‐inspired protocols (34.4% vs. 21.3%, p < 0.001). Patients < 30 years showed better CR (58.3%, p = 0.026) and longer survival (median OS 15 vs. 8 months, p < 0.001). Median OS for the cohort was 11 months, with a 5‐year OS of 22.4%. High‐risk patients had inferior OS (11 vs. 14 months, p = 0.036), while no difference was observed between Ph + and Ph– (12 vs. 11 months, p = 0.319).
Conclusion
Adult Ecuadorian patients with B‐ALL show lower survival than international cohorts, mainly due to high treatment‐related mortality and limited transplantation access. Age was independently associated with response and OS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- IRHED Medical Specialties Center, Guayaquil, Ecuador.
- Hematology Service, Carlos Andrade Marín Hospital, Quito, Ecuador.
- Hemato-Oncology and Medicine Transfusion Department, Solca Cancer Institute, Manabí, Ecuador.
- Hematology Service, Teodoro Maldonado Carbo Hospital, Guayaquil, Ecuador.
- Department of Hematology, Abel Gilbert Ponton Hospital, Guayaquil, Ecuador.
- Angela Serra Association for Cancer Research, Lecce, Italy.
ORCID-Profile: Brenner Sabando
Förderung
- Varifarma Ecuador
Zitieren
APA
Sabando, B., Quinonez, J., Orquera, A., Navarrete, D., Ramírez, J., Sanchez, L., Chisesi, T., Oliveros, J., Pacheco, M. A., Trujillo, M. C., Plaza, C., Lochamin, R., & Jimmy Martin, D. (2026). A Multicenter Survival Analysis of Adults Type B‐Acute Lymphoblastic Leukemia in Ecuador. A Retrospective Study of the Real World. Cancer Medicine. https://doi.org/10.1002/cam4.71625
Vancouver
Sabando B, Quinonez J, Orquera A, Navarrete D, Ramírez J, Sanchez L, et al. A Multicenter Survival Analysis of Adults Type B‐Acute Lymphoblastic Leukemia in Ecuador. A Retrospective Study of the Real World. Cancer Medicine. 2026. doi:10.1002/cam4.71625
BibTeX
@article{Sabando2026,
author = {Sabando, Brenner and Quinonez, Jairo and Orquera, Andrés and Navarrete, Danilo and Ramírez, Jhoanna and Sanchez, Lorena and Chisesi, Teodoro and Oliveros, Jorge and Pacheco, María A and Trujillo, María C and Plaza, Carlos and Lochamin, Rafael and Jimmy Martin, D},
title = {A Multicenter Survival Analysis of Adults Type B‐Acute Lymphoblastic Leukemia in Ecuador. A Retrospective Study of the Real World},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.71625}
}
EUVIMED